Compare FNWD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | IVVD |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.6M | 692.7M |
| IPO Year | N/A | 2021 |
| Metric | FNWD | IVVD |
|---|---|---|
| Price | $35.59 | $2.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $34.00 | $8.75 |
| AVG Volume (30 Days) | 28.3K | ★ 5.2M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $66,563,999.00 | $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | $8.03 | $171.40 |
| P/E Ratio | $19.29 | ★ N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $26.12 | $0.35 |
| 52 Week High | $39.99 | $3.07 |
| Indicator | FNWD | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 56.55 |
| Support Level | $37.45 | $2.52 |
| Resistance Level | $38.72 | $2.85 |
| Average True Range (ATR) | 0.87 | 0.21 |
| MACD | -0.46 | 0.02 |
| Stochastic Oscillator | 3.72 | 50.60 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.